Feb 15, 2018 — Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for Q4 of $2.1 million, doubling revenue for the year, and signed agreements for 337 instruments. Contracts for customer evaluations covered 259 instruments while revenue placements totaled 78 across the U.S., European, and Middle East regions. Net […]
Accelerate Diagnostics to Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco
Jan 04, 2018 — Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer is scheduled to speak at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place Wednesday, January 10, 2018 at 10:30 AM, Pacific Time. See all press releases.
UAMS in Arkansas Adopts the Accelerate Pheno™ system
Dec 20, 2017 — Accelerate Diagnostics, Inc. is pleased to announce that the Accelerate Pheno™ system is the latest addition to the UAMS Clinical Microbiology Laboratory’s array of industry-redefining technologies for the treatment of infectious diseases.
PRMC Is the first hospital in Maryland to Adopt the Pheno™ System
Dec 06, 2017 — Accelerate Diagnostics, Inc. is pleased to announce that Peninsula Regional Medical Center (PRMC) has implemented the Accelerate Pheno™ system for patients. PRMC is the first hospital in Maryland to adopt this system, which was approved by the Food & Drug Administration earlier this year. PRMC said it made this investment in antimicrobial stewardship in the […]
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
14 - 16 February 2018
15 - 16 February 2018
February 25 - 27, 2018
San Antonio, TX
June 7 - 11, 2018
5 - 8 February 2018
5 February 2018
December 18-19, 2017
Palais des Congrès de Paris
October 4–8, 2017
June 1–5, 2017
May 10–13, 2017
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.